Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.

Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer. Medicine (Baltimore) (2016) 0.78

Targeting MAPK Signaling in Age-Related Macular Degeneration. Ophthalmol Eye Dis (2016) 0.77

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget (2016) 0.76

Confronting the Care Delivery Challenges Arising from Precision Medicine. Front Oncol (2016) 0.75

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. PLoS One (2017) 0.75

Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncol (2017) 0.75

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol (2016) 0.75

The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Oncogene (2017) 0.75

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int J Mol Sci (2017) 0.75

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis (2017) 0.75

Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther (2017) 0.75

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev (2001) 14.02

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev (2004) 9.54

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88

MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58

Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature (2013) 5.04

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02

Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82

Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 4.76

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70

A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol (1996) 4.61

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26

Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst (2001) 4.25

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther (2007) 4.16

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21

Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09

The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol (2008) 2.98

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96

Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol (2007) 2.69

Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta (2006) 2.28

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol (2006) 2.25

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22

Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 1.92

MEK and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.90

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell (2014) 1.88

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol (2009) 1.81

Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene (2004) 1.80

The clinical development of MEK inhibitors. Nat Rev Clin Oncol (2014) 1.79

BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther (2011) 1.77

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal (2011) 1.77

Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol Cell Biol (1996) 1.63

MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol (2009) 1.60

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52

The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene (2004) 1.51

Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44

Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. Mol Cell (2009) 1.44

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell (2014) 1.43

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39

Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia (1997) 1.29

Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol (2015) 1.27

Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol (2004) 1.25

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res (2011) 1.24

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther (2011) 1.24

Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol (2004) 1.21

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther (2010) 1.19

Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16

B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene (2012) 1.12

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res (2014) 1.10

Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc Natl Acad Sci U S A (2013) 1.10

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer (2013) 1.10

RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09

BRAF inhibitors in cancer therapy. Pharmacol Ther (2013) 1.07

Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene (1999) 1.06

New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res (2014) 1.04

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res (2012) 1.03

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02

Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nat Commun (2011) 1.02

Cancer: Drug for an 'undruggable' protein. Nature (2013) 1.01

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J (2013) 0.99

Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res (2011) 0.94

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res (2012) 0.91

Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res (2012) 0.88

The raf inhibitor paradox: unexpected consequences of targeted drugs. Cancer Cell (2010) 0.88

ERK-1 MAP kinase prevents TNF-induced apoptosis through bad phosphorylation and inhibition of Bax translocation in HeLa Cells. J Cell Biochem (2009) 0.87

Adaptor SKAP-55 binds p21 activating exchange factor RasGRP1 and negatively regulates the p21-ERK pathway in T-cells. PLoS One (2008) 0.85

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer (2013) 0.84

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 0.84

MAPK p38: alternative and nonstressful in T cells. Nat Immunol (2005) 0.83

pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner. Mol Oncol (2013) 0.83

Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. Carcinogenesis (2007) 0.81

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 0.81

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochem Soc Trans (2012) 0.79

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer. Biochem Soc Trans (2014) 0.79